İzlanda - İzlandaca - LYFJASTOFNUN (Icelandic Medicines Agency)

boehringer ingelheim international gmbh* - tiotropii bromidum inn; olodaterolum hýdróklóríð - innöndunarlausn - 2,5/2,5 míkróg

İzlanda - İzlandaca - LYFJASTOFNUN (Icelandic Medicines Agency)

janssen-cilag ab - topiramatum inn - hart hylki - 15 mg

Avrupa Birliği - İzlandaca - EMA (European Medicines Agency)

novartis europharm limited - rivastigmin - alzheimer disease; parkinson disease; dementia - psychoanaleptics, - einkennum meðferð vægt til nokkuð alvarlega alzheimer heilabilun. einkennum meðferð vægt til nokkuð alvarlega heilabilun í sjúklinga með sjálfvakin parkinsonsveiki.

İzlanda - İzlandaca - LYFJASTOFNUN (Icelandic Medicines Agency)

viatris limited - naproxenum inn - tafla - 500 mg

İzlanda - İzlandaca - LYFJASTOFNUN (Icelandic Medicines Agency)

recordati ireland limited* - metoprololum súkkínat - forðatafla - 23,75 mg

İzlanda - İzlandaca - LYFJASTOFNUN (Icelandic Medicines Agency)

aspen pharma trading limited - busulfanum inn - filmuhúðuð tafla - 2 mg

İzlanda - İzlandaca - LYFJASTOFNUN (Icelandic Medicines Agency)

viatris limited - tamoxifenum cítrat - tafla - 20 mg

Avrupa Birliği - İzlandaca - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, kvarta stutt og long-term - sykursýki, tegund 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Avrupa Birliği - İzlandaca - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, kvarta stutt og long-term - sykursýki, tegund 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 og 5. 1 fyrir tiltæk gögn um mismunandi samsetningar).

Avrupa Birliği - İzlandaca - EMA (European Medicines Agency)

novartis europharm limited  - vildagliptin, kvarta stutt og long-term - sykursýki, tegund 2 - lyf notuð við sykursýki - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.